Cda - cytidine deaminase Gene

Also Known as 2210401N16Rik

Species: Mus musculus

Gene Type: protein coding
Gene ID: 72269

Summary

Enables cytidine deaminase activity and identical protein binding activity. Involved in UMP salvage. Is active in cytosol. Is expressed in several structures, including alimentary system; eye; genitourinary system; heart; and nervous system. Human ortholog(s) of this gene implicated in lung non-small cell carcinoma. Orthologous to human CDA (cytidine deaminase). [provided by Alliance of Genome Resources, Apr 2022]

Cda Products (1)

mRNA Protein Name
NM_028176.1 NP_082452.1 cytidine deaminase

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence Références Source
enables cytidine deaminase activity IDA
IDA: Inferred from direct assay
5651639 MGI
enables identical protein binding IPI
IPI: Inferred from physical interaction
11591653 MGI
Biological Process GO Annotation Evidence Références Source
involved in UMP salvage IDA
IDA: Inferred from direct assay
6498945 MGI
Cellular Component GO Annotation Evidence Références Source
is active in cytosol IDA
IDA: Inferred from direct assay
5651639 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

cytidine deaminase

  • cytidine aminohydrolase

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (3)
Cat. No. Nom du produit Effect
Pureté Rare Diseases
HY-13599 Cladribine 99.96% Yes
HY-109081 Cedazuridine 99.72% Unkown
HY-109081A Cedazuridine hydrochloride / Unkown

Clinical Phase

Bioactive Molecules (4)
Cat. No. Nom du produit Effect
Pureté Phase
HY-12885A 2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt Activator 99.91% Phase 2
HY-12885B 2’3’-c-di-AM(PS)2 (Rp,Rp) ammonium salt Activator 99.89% Phase 2
HY-12885 2’3’-c-di-AM(PS)2 (Rp,Rp) Activator 99.85% Phase 2
HY-15345A Tetrahydrouridine Inhibitor 99.91% Phase 2

Pre-clinical Phase

Bioactive Molecules (18)
Cat. No. Nom du produit
Effect
Pureté
Rare Diseases
HY-15345 Tetrahydrouridine dihydrate Inhibitor 99.86% Yes
HY-12885C 2’3’-c-di-AM(PS)2 (Rp,Rp) enantiomer ammonium salt Inducer 98.94% Unkown
HY-Y1058 Benzohydroxamic acid Inhibitor 99.95% Unkown
HY-13599S3 Cladribine-13C3,15N3 / Unkown
HY-13599S4 Cladribine-13C,15N2 / Unkown
HY-15345AS Tetrahydrouridine-d3 / Unkown
HY-171540 AnCDA-IN-1 Inhibitor / Unkown
HY-171541 CDA-IN-1 Inhibitor / Unkown
HY-171542 CDA-IN-2 Inhibitor / Unkown
HY-172523 CDA-IN-3 / Unkown
HY-RS02282 CDA Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-13599S Cladribine-d4 / Unkown
HY-13599S1 Cladribine-13C5,15N2 / Unkown
HY-13599S2 Cladribine-15N / Unkown
HY-173448 CDA-IN-4 Inhibitor / Unkown
HY-181002 CDA-IN-5 Inhibitor / Unkown
HY-RS17118 Cda Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23563 Cda Rat Pre-designed siRNA Set A Pre-designed Set / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Cda NCBI NCBI:978